Breaking News Instant updates and real-time market news.

VBLT

VBL Therapeutics

$4.55

0.05 (1.11%)

08:21
06/19/17
06/19
08:21
06/19/17
08:21

VBL Therapeutics provides update on long-term survival in Phase 2 trials

VBL Therapeutics provided an update on the long term status and survival of patients from three completed Phase 2 trials, which investigated the company's lead candidate, VB-111, respectively in recurrent glioblastoma, or rGBM, recurrent platinum-resistant ovarian cancer and radioiodine refractory differentiated thyroid cancer. All three trials had previously shown signals of an overall survival benefit for VB-111. The company has continued to follow the survival of patients from these trials. "We are pleased to report that in all three indications over 50% of patients have achieved long term survival following treatment with VB-111 as detailed below. Each of these Phase 2 trials enrolled difficult to treat patients for whom prior treatments had failed," said Prof. Dror Harats, CEO of VBL Therapeutics. "In addition, we continue to follow patients from our Phase 1 studies, who responded to VB-111 and have now survived for more than 5 years, although they were end-stage patients whose tumors had previously progressed in spite of several lines of therapy. We are now conducting pivotal trials with the goal of investigating these survival benefits and providing data to support regulatory approval and commercialization of VB-111. Our GLOBE pivotal trial in rGBM has completed enrollment and we expect top line data from the full dataset becoming available in early 2018. We expect patient enrollment in our planned Phase 3 OVAL study in ovarian cancer to begin in the second half of 2017. In addition, we plan to launch a combination study of VB-111 with a checkpoint inhibitor in lung cancer by year-end 2017."

VBLT VBL Therapeutics
$4.55

0.05 (1.11%)

11/29/16
ROTH
11/29/16
NO CHANGE
Target $17
ROTH
Buy
VBL Therapeutics thyroid study points in right direction, says Roth Capital
Roth Capital analyst Joseph Pantginis notes that VBL Therapeutics has announced positive follow-up overall survival data from the Phase 2 thyroid cancer study with VB-111. The analyst believes VB-111 represents a "strong potential option" for patients with recurrent glioblastoma and looks forward to clinical progress in the Phase 3 rGBM study. Pantginis projects upside from future clinical updates, expansion opportunities for new indications as well as partnership potential for VB-111. He reiterates a Buy rating and $17 price target on the shares.
11/29/16
ROTH
11/29/16
NO CHANGE
ROTH
VBL Therapeutics mentioned positively at Roth Capital
06/28/16
HCWC
06/28/16
INITIATION
Target $11
HCWC
Buy
VBL Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started VBL Therapeutics with a Buy rating and $11 price target.

TODAY'S FREE FLY STORIES

BBD

Banco Bradesco

09:31
01/22/18
01/22
09:31
01/22/18
09:31
Upgrade
Banco Bradesco rating change  »

Banco Bradesco upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIVI

II-VI

$52.95

0.9 (1.73%)

09:30
01/22/18
01/22
09:30
01/22/18
09:30
Downgrade
II-VI rating change  »

II-VI downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

SANM

Sanmina

09:30
01/22/18
01/22
09:30
01/22/18
09:30
Recommendations
Sanmina analyst commentary  »

Sanmina price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

RELX

RELX

09:30
01/22/18
01/22
09:30
01/22/18
09:30
Downgrade
RELX rating change  »

RELX downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

09:29
01/22/18
01/22
09:29
01/22/18
09:29
Recommendations
Schlumberger analyst commentary  »

Schlumberger price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:28
01/22/18
01/22
09:28
01/22/18
09:28
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

HAL

Halliburton

09:27
01/22/18
01/22
09:27
01/22/18
09:27
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

WP

Worldpay

09:27
01/22/18
01/22
09:27
01/22/18
09:27
Initiation
Worldpay initiated  »

Worldpay reinstated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:26
01/22/18
01/22
09:26
01/22/18
09:26
Hot Stocks
Halliburton says sees new effective tax rate approximately 21%-23% »

Says new tax rate a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

TXN

Texas Instruments

$116.83

0.42 (0.36%)

09:25
01/22/18
01/22
09:25
01/22/18
09:25
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

09:25
01/22/18
01/22
09:25
01/22/18
09:25
General news
IMF revised its global growth outlook higher, in part on U.S. tax cuts »

IMF revised its global…

PAYC

Paycom

, ALRM

Alarm.com

$38.73

-0.7 (-1.78%)

09:25
01/22/18
01/22
09:25
01/22/18
09:25
Conference/Events
Jefferies software analyst holds an analyst/industry conference call »

Software Analyst DiFucci…

PAYC

Paycom

ALRM

Alarm.com

$38.73

-0.7 (-1.78%)

CA

CA Technologies

$34.07

-0.12 (-0.35%)

RHT

Red Hat

ORCL

Oracle

SSNC

SS&C

$49.98

0.04 (0.08%)

VMW

VMware

CTXS

Citrix

$92.72

1.34 (1.47%)

MSFT

Microsoft

$90.00

-0.1 (-0.11%)

SYMC

Symantec

$27.46

0.21 (0.77%)

PANW

Palo Alto Networks

APTI

Apptio

$24.79

0.56 (2.31%)

CHKP

Check Point

$104.48

1.28 (1.24%)

NICE

Nice

$93.60

-0.23 (-0.25%)

SPLK

Splunk

$89.94

-1.49 (-1.63%)

RNG

RingCentral

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 12

    Feb

  • 26

    Feb

  • 27

    Feb

DCIX

Diana Containerships

$3.24

0.09 (2.86%)

09:23
01/22/18
01/22
09:23
01/22/18
09:23
Hot Stocks
Diana Containerships sells two post-Panamax container vessels for $22M »

Diana Containerships has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAA

CalAtlantic

, LEN

Lennar

09:23
01/22/18
01/22
09:23
01/22/18
09:23
Recommendations
CalAtlantic, Lennar analyst commentary  »

CalAtlantic price target…

CAA

CalAtlantic

LEN

Lennar

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

09:21
01/22/18
01/22
09:21
01/22/18
09:21
Downgrade
South Jersey Industries rating change  »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

KBH

KB Home

09:20
01/22/18
01/22
09:20
01/22/18
09:20
Recommendations
KB Home analyst commentary  »

KB Home price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

09:20
01/22/18
01/22
09:20
01/22/18
09:20
General news
U.S. Producer Sentiment Tailwinds Extend Into 2018: »

U.S. Producer Sentiment…

TOL

Toll Brothers

09:19
01/22/18
01/22
09:19
01/22/18
09:19
Recommendations
Toll Brothers analyst commentary  »

Toll Brothers price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$179.64

4.16 (2.37%)

, HAL

Halliburton

09:19
01/22/18
01/22
09:19
01/22/18
09:19
Hot Stocks
On The Fly: Pre-market Movers »

UP AFTER EARNINGS: Wynn…

WYNN

Wynn Resorts

$179.64

4.16 (2.37%)

HAL

Halliburton

PETS

PetMed Express

$53.24

2.67 (5.28%)

OPB

Opus Bank

$28.70

0.05 (0.17%)

BCRX

BioCryst

$5.59

-0.09 (-1.58%)

IDRA

Idera Pharmaceuticals

$2.55

0.145 (6.03%)

ANF

Abercrombie & Fitch

AAPL

Apple

$178.46

-0.8 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 01

    Feb

CYTX

Cytori Therapeutics

$0.40

-0.0188 (-4.48%)

09:19
01/22/18
01/22
09:19
01/22/18
09:19
Hot Stocks
Cytori Therapeutics completes enrollment in Habeo trial for scleroderma »

Cytori Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBS

UBS

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Periodicals
UBS to start moving jobs in early 2018 ahead of Brexit, Telegraph reports »

UBS will begin shifting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

PHM

PulteGroup

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Recommendations
PulteGroup analyst commentary  »

PulteGroup price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Options
Overnight activity included 111 trades in SPX and 29 trades in VIX »

111 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RF

Regions Financial

09:17
01/22/18
01/22
09:17
01/22/18
09:17
Upgrade
Regions Financial rating change  »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.